Your browser doesn't support javascript.
loading
Low frequency of c-MPL gene mutations in Iranian patients with Philadelphia-negative myeloproliferative disorders.
Ghotaslou, A; Nadali, F; Chahardouli, B; Alizad Ghandforosh, N; Rostami, S H; Alimoghaddam, K; Ghavamzadeh, A.
Afiliação
  • Ghotaslou A; MS.c Student , Department of Hematology,School of Allied Medical Sciences , Tehran university of Medical Sciences, Tehran , Iran.
  • Nadali F; Associate Professor, Departement of Hematology, School of Allied Medical Sciences , Tehran university of Medical Sciences , Tehran, Iran.
  • Chahardouli B; Assistant Professor, Hematology-Oncology and Stem cell Transplantation Research Center, Tehran university of Medical Sciences, Tehran, Iran.
  • Alizad Ghandforosh N; MS.c Student, Hematology-Oncology and Stem cell Transplantation Research Center, Tehran university of Medical Sciences, Tehran, Iran.
  • Rostami SH; Assistant Professor, Hematology-Oncology and Stem cell Transplantation Research Center, Tehran university of Medical Sciences, Tehran, Iran.
  • Alimoghaddam K; Professor, Hematology-Oncology and Stem cell Transplantation Research Center, Tehran university of Medical Sciences, Tehran, Iran.
  • Ghavamzadeh A; Professor, Hematology-Oncology and Stem cell Transplantation Research Center, Tehran university of Medical Sciences, Tehran, Iran.
Iran J Ped Hematol Oncol ; 5(1): 43-9, 2015.
Article em En | MEDLINE | ID: mdl-25914801
ABSTRACT

BACKGROUND:

Myeloproliferative disorders are a group of diseases characterized by increased proliferation of myeloid lineage. In addition to JAK2V617F mutation, several mutations in the c-MPL gene have been reported in patients with philadelphia-negative chronic myeloproliferative disorders that could be important in the pathogenesis of diseases. The aim of the present study was to investigate the frequency of c-MPL and JAK2V617F mutations in Iranian patients with Philadelphia-negativemyeloproliferative disorders. MATERIAL AND

METHODS:

Peripheral blood samples were collected from 60 patients with Philadelphia-negative MPD) Subgroups ET and PMF) and 25 healthy subjects as control group. The mutation status of c-MPL and Jak2V617F were investigated by using Amplification-refractory mutation system (ARMS) and Allele-Specific PCR (AS-PCR), respectively. The results were confirmed by sequencing.

RESULTS:

Among 60 patients, 34 (56.6%) and 1(1.7%) had Jak2V617F and c-MPL mutation, respectively. Patients with Jak2V617F mutation had higher WBC counts and hemoglobin concentration than those without the mutation (p= 0.005, p=0.003). In addition, for all healthy subjects in control group, mutations were negative.

CONCLUSIONS:

The present study revealed that the c-MPL mutations unlike the Jak2V617F mutations are rare in Iranian patients with Ph-negative MPNs and the low mutation rate should be considered in the design of screening strategies of MPD patients.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Iran J Ped Hematol Oncol Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Irã

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Iran J Ped Hematol Oncol Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Irã